Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MARS1 | P56192 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 5/20 | 0.35 |
| ▸ | CNR2 | P34972 | 4/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1302690 | 0.83 | ALDH1A1 (0.40) | CHRM1PTGS1KMT2ACNR1 | |
| SCHEMBL3250915 | 0.75 | MARS1 (0.39) | MARS1LMNANR3C2CNR1CNR2 | |
| SCHEMBL2846887 | 0.75 | MARS1 (0.41) | MARS1LMNAKMT2ANR3C2P2RX7 | |
| SCHEMBL1303913 | 0.72 | CHRM1 (0.35) | MARS1CHRM1PTGS1LMNAKMT2A | |
| SCHEMBL1722410 | 0.72 | P2RX7 (0.39) | MARS1KMT2ANR3C2CNR1P2RX7 | |
| SCHEMBL564412 | 0.70 | MDM2 (0.44) | PTGS1NR3C2 | |
| SCHEMBL28575589 | 0.68 | L3MBTL1 (0.40) | CNR1CNR2 | |
| SCHEMBL24875683 | 0.68 | PSEN1 (0.48) | CHRM1PTGS1KMT2A | |
| SCHEMBL30192806 | 0.68 | PSEN1 (0.48) | CHRM1PTGS1KMT2A | |
| SCHEMBL20550778 | 0.67 | LMNA (0.57) | MARS1LMNANR3C2ARP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269757-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2011-11-03 | — | — | US | disclosed |
| EP-2344492-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GenKyoTex SA (CH) | 2011-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269757-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | NOX1, NOX4, CYBB | MARS1 3708/4885CHRM1 1157/4885PTGS1 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.